{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:39:28Z","timestamp":1789684768248,"version":"4.0.1"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2024,12,1]]},"abstract":"Importance<\/jats:title>Nail lichen planus has the potential to cause permanent destruction of the nail unit and remains challenging to treat. Studies suggest that low-dose naltrexone is a safe and potentially effective treatment for other dermatologic conditions, including lichen planopilaris.<\/jats:p><\/jats:sec>Objective<\/jats:title>To assess the effectiveness of low-dose naltrexone in treating nail lichen planus.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This case series evaluates 7 adult patients with biopsy-proven nail lichen planus who were treated with low-dose naltrexone (3 mg per day) at the University of Miami dermatologic clinics from November 2022 to December 2023. The data were analyzed in March 2024. Patients were treated for at least 2 months and had in-person follow-up evaluation while receiving treatment.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The main outcome was posttreatment clinical nail lichen planus severity index, which was scored as clear, mild, moderate, or severe. Patients were evaluated for oral and cutaneous disease during the course of treatment. Tolerance and adverse events were noted.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 7 patients (mean [range] age, 60 [38-77] years; 3 female individuals) were included. All but 1 patient had been previously treated and did not respond to at least 1 prior treatment (median [range], 2.5 [0-4.0] treatments). Treatment duration ranged from 2 to 11 months. Clinical response was observed in 4 of 7 patients, with an overall 35% reduction in nail lichen planus severity index. Two patients with severe disease achieved a reduction to mild severity. None of the patients had to discontinue low-dose naltrexone due to adverse events, and no adverse events were reported.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>The results of this study suggest that low-dose naltrexone may be a therapeutic approach for treating nail lichen planus. Further controlled studies are warranted to better understand its clinical efficacy and safety profile in treating nail lichen planus.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2024.4098","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T15:42:25Z","timestamp":1730302945000},"page":"1334","source":"Crossref","is-referenced-by-count":7,"title":["Low-Dose Naltrexone Use in Biopsy-Proven Lichen Planus of the Nails"],"prefix":"10.1001","volume":"160","author":[{"given":"Eric R.","family":"Bray","sequence":"first","affiliation":[{"name":"Dr Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian W.","family":"Morrison","sequence":"additional","affiliation":[{"name":"Dr Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"dbr240018r1","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.det.2020.12.002","article-title":"Review of nail lichen planus: epidemiology, pathogenesis, diagnosis, and treatment.","volume":"39","author":"Gupta","year":"2021","journal-title":"Dermatol Clin"},{"issue":"2","key":"dbr240018r2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1001\/jamadermatol.2018.4093","article-title":"Utility of naltrexone treatment for chronic inflammatory dermatologic conditions: a systematic review.","volume":"155","author":"Ekelem","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"11","key":"dbr240018r3","first-page":"1140","article-title":"Novel treatment using low-dose naltrexone for lichen planopilaris.","volume":"16","author":"Strazzulla","year":"2017","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"dbr240018r4","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.34169","article-title":"Oral low-dose naltrexone in the treatment of frontal fibrosing alopecia and lichen planopilaris: an uncontrolled open-label prospective study.","volume":"15","author":"Hamel","year":"2023","journal-title":"Cureus"},{"issue":"6","key":"dbr240018r5","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1016\/j.jaad.2020.02.056","article-title":"Isolated nail lichen planus: An expert consensus on treatment of the classical form.","volume":"83","author":"Iorizzo","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"1-2","key":"dbr240018r6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1159\/000445544","article-title":"Trachyonychia and twenty-nail dystrophy: a comprehensive review and discussion of diagnostic accuracy.","volume":"2","author":"Jacobsen","year":"2016","journal-title":"Skin Appendage Disord"},{"issue":"7","key":"dbr240018r7","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.3390\/biomedicines11072037","article-title":"Endogenous opioids in Crohn\u2019s disease.","volume":"11","author":"Martyniak","year":"2023","journal-title":"Biomedicines"},{"issue":"11","key":"dbr240018r8","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1093\/pm\/pnad074","article-title":"Low-dose naltrexone\u2019s utility for non-cancer centralized pain conditions: a scoping review.","volume":"24","author":"Rupp","year":"2023","journal-title":"Pain Med"},{"issue":"10","key":"dbr240018r9","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/j.1600-0714.2012.01169.x","article-title":"TLR4 and TLR9 are induced in oral lichen planus.","volume":"41","author":"Siponen","year":"2012","journal-title":"J Oral Pathol Med"},{"issue":"2","key":"dbr240018r10","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1080\/09546634.2020.1774488","article-title":"The efficacy and safety of oral low dose naltrexone versus placebo in the patients with lichen planopilaris: a randomized controlled clinical trial.","volume":"33","author":"Lajevardi","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"dbr240018r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.03.010","article-title":"Attenuation of disease process following treatment with low-dose naltrexone in patients with frontal fibrosing alopecia and lichen planopilaris: a retrospective study.","author":"Yossef","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"dbr240018r12","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1111\/bjd.18861","article-title":"Improvement of Hailey-Hailey disease with low-dose naltrexone.","volume":"182","author":"Jasans-Barcel\u00f3","year":"2020","journal-title":"Br J Dermatol"},{"issue":"3","key":"dbr240018r13","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1001\/jamadermatol.2017.5463","article-title":"Variable response to naltrexone in patients with Hailey-Hailey disease.","volume":"154","author":"Cao","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"4","key":"dbr240018r14","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/MCG.0b013e3182702f2b","article-title":"Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn\u2019s disease: a pilot study.","volume":"47","author":"Smith","year":"2013","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"dbr240018r15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.31138\/mjr.34.1.1","article-title":"Low-dose naltrexone in rheumatological diseases.","volume":"34","author":"de Carvalho","year":"2023","journal-title":"Mediterr J Rheumatol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2825430\/jamadermatology_bray_2024_br_240018_1734108404.3745.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T16:01:05Z","timestamp":1734537665000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2825430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,1]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2024.4098","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,1]]}}}